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Background: The natural history of patients commencing dialysis in East Yorkshire is not well characterised and
there is little convincing evidence which has studied the impact of potential factors prior to commencement of
renal replacement therapy (RRT) at predicting mortality during dialysis. The aim of this study was to examine the
previously published 5-year data on end stage renal disease and co-morbid risk factors for mortality at 10 years.
Methods: An observational cohort study of subjects commencing dialysis in 2001/02 in East Yorkshire with a mean
follow up from dialysis initiation of 8.8 years. Predictors of mortality were determined by univariate, multivariate
analysis and survival via Kaplan-Meier analysis. Assessment of the utility of the Tangri risk calculator was carried out
in addition to slope change in eGFR prior to dialysis commencement.
Results: Baseline characteristics and the preferred mode of dialysis remained concordant with the original trial. The
mortality rate at the end of the study period was 60% (56/94) with 30% (29) of patients having been transplanted.
Highlighted in the 5 year data a significant proportion of mortality was made up of vascular disease and sepsis
(71%) but this proportion had decreased (57%) by 10 years. Cardiac disease was the commonest cause of death but
notably in 18% of patients, death was related to dialysis or withdrawal of treatment. Vascular disease and diabetes
remained independent risk factors and predicative of mortality. Calcium - phosphate product which was associated
in the early years with mortality was not in later years. Use of the risk calculator was predictive of commencement
of RRT but not mortality but slope change in eGFR was predictive of mortality.
Conclusions: Although diabetes and vascular disease remained predictive of mortality, interestingly
calcium-phosphate levels are no longer significant and may be a more specific predictor of early cardiac mortality.
Slope eGFR changes prior to RRT are a predictor of mortality. We speculate that aggressive management of cardiac
risk factors in addition to early transplantation may be key to influencing the impact of survival in this cohort in
addition to possible measures to delay renal progression.
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Chronic kidney disease (CKD) has been increasingly recog-
nized as a risk factor for mortality and cardiovascular dis-
ease. In the United Kingdom at least 7% of the adult
population have an eGFR of less than 60 mls/min/1.73 m2
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reproduction in any medium, provided the orfor end stage renal disease (ESRD) [1], with an increasingly
aging population suffering from a significant number of
co-morbidities these figures continue to increase at 5% per
annum [2].
Despite advances in the treatment of chronic renal fail-
ure the prognosis remains poor. Timely identification of
risk factors that predispose or exacerbate CKD will help to
reduce the morbidity and mortality of those who will need
future renal replacement therapy (RRT). In particular, there
is strong evidence for cardiovascular risk factors being as-
sociated with deterioration in patients’ renal function andl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[3]. This generates scope for primary preventative interven-
tions, ameliorating, not only classical modifiable risk factors
such as; smoking, hypertension, diabetes mellitus and
hyperlipidaemia but also non-traditional risk factors such
as; functional iron deficiency, anaemia, insulin resistance
and vitamin D deficiency [4-6]. Preventive measures are
not only needed to prevent disease states occurring but also
are required to modify outcomes once disease has been
established. Secondary and tertiary preventative measures
show that modifying a patient’s risk factors on dialysis ther-
apy improves survival and quality of life [7-9]. In addition
measures delaying renal progression, (eGFR being a strong
surrogate cardiac risk factor), and hence cardiovascular risk
may have a significant impact on future survival [10,11].
Previously we have described the 1 and 5-year results
of an analysis of factors and co-morbidities predictive of
mortality in a prospective study of a cohort of 94 dialysis
patients [12]. Risk factors, which were analysed at 5
years, confirmed that an elevated calcium phosphate
product, diabetes mellitus, vascular disease (such as per-
ipheral vascular disease) and older age at the start of
dialysis were independently predictive of mortality. In
addition, the study identified low haemoglobin and lower
eGFR prior to commencement of dialysis as good pre-
dictors of early mortality reflecting findings from other
investigators [13,14]. We now present the extended
ten-year data to highlight the impact and changes in risk
factor profile and also further analysis using the Tangri
risk calculator [15] and measures of slope change in
eGFR prior to commencement of RRT.
Methods
The design of the study was an observational cohort,
taken from patients receiving dialysis from the Hull and
East Yorkshire Hospital Services over a 10-year period.
Re-analysis of the data was performed on the same
cohort of 94 patients, the database from the 5-year
period having been adjusted to include changes in pa-
tient outcomes. Previously analysed risk factors were
sought for revalidation of predicting mortality.
The NHS Hospital Trust Research and Development
committee approved the study as part of regional devel-
opment of its dialysis service. All patients are globally
consented for use of patient data prior to initiating dialy-
sis with the service as set out by the Trust’s renal hand-
book policy. Formal written consent was not required as
any subsequent interventions made during the observa-
tional study were aimed at improving clinical care based
on the current guidelines, best available evidence and
clinical expertise.
The 94 patients had been selected from the East
Yorkshire region having commenced renal replacement
therapy (RRT) in the form of haemodialysis or peritonealdialysis in the year 2001/2002. All patients presenting for
dialysis therapy were included except patients dialysing for
less than 90 days, who were considered to be acute. Patient
characteristics are described in the original study [12]. All
cause mortality was the primary outcome measure and
was used as a comparison to the previous 5-year data.
Factors analysed at the time of RRT commencement
included; age at the start of dialysis, gender, smoking sta-
tus, previous referral eGFR and eGFR at RRT initiation
(measured by the four-variable Modification of Diet in
Renal Disease equation), duration of renal care, renal
disease aetiology, dialysis mode (haemodialysis and peri-
toneal dialysis), form of access, dialysis planning, dia-
betes and left ventricular hypertrophy (LVH) (diagnosed
by ECG or trans-thoracic echocardiography).
Presence of significant co-morbidities at the start of RRT
including; diabetes, vascular disease (defined from the
presence of symptoms of peripheral vascular disease, clin-
ical findings confirming vascular compromise, investiga-
tions confirming compromise – e.g. doppler, angiography
or intervention with angioplasty or surgery (peripheral
artery bypass grafts)), chronic obstructive pulmonary
disease, ischaemic heart disease, cerebrovascular dis-
ease and visceral malignancy were studied together to
stratify subjects into low-medium and high risk groups
on mortality.
Modifiable biochemical markers of haemoglobin,
serum albumin, triglycerides, cholesterol, calcium and
phosphate at the start of RRT were also included in the
analysis. Calcium-phosphate product was split into quar-
tiles and the upper quartile was compared to the 3 lower
quartiles when comparing effect on mortality.
Using the Tangri risk calculator (a predictive model for
progression of chronic kidney disease to renal failure) the
risk of entering end-stage renal failure (ERRF) was calcu-
lated in the cohort [15]. Calculations were made based
on; age, sex, eGFR, calcium, phosphate, albumin and
bicarbonate, before undertaking renal replacement ther-
apy. The stratification in level of risk was: 0–10% = Low
risk, 10–20% = intermediate risk and >20% risk of entering
ESRF =High risk.
The slope eGFRs for this cohort were calculated using
linear regression from time of presentation to a neph-
rologist and just before commencing RRT. Those crash
landing to dialysis within 90 days were censored from
the analysis. The cohort was split into quartiles. The
upper quartile (composed of the fastest decreasing slope)
was compared against the lower three quartiles for mor-
tality using Kaplan-Meier survival analysis.
Statistical analysis
All continuous data are expressed as means (standard de-
viation (sd)), medians (interquartile ranges). All categorical
data are expressed as number and percentage.
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tality rate at 10 years (Table 1). The independent variables
were compared between those who were alive or dead at
10 years using a chi-square test tor continuous variables
and chi-square tests for categorical variables (Table 2).
For survival over 10 years based on time to death or last
follow-up, the Kaplan-Meier method was used. Log rank
tests were used to explore the relationship with categorical
independent variables (e.g. presence of vascular disease,
diabetes and age (less than or equal to 65 years vs greater
than 65 years). This data is presented in Table 3.
To further investigate mortality over 10 years, Cox
proportional hazards modelling was used, with time to
death or last follow-up as the dependant variable, and a
range of categorical and continuous variables included
in the model (Table 4). The log-log plot is one way to as-
sess graphically whether the assumption of proportional
hazards was reasonable. For the assumption to hold then
the log-log plot should show the separate lines as ap-
proximately parallel to each other.
All statistical analyses were completed on SPSS for
Windows (v19). A p-value of < 0.05 was considered sta-
tistically significant.
Results
The cohort of patients was followed up for a median of
8.7 years [mean of 8.8 ± 0.3 years] from the date each pa-
tient commenced dialysis therapy in 2001/2002 and a
median of 10.5 years [mean of 11.9 ± 4.2 years] from
presentation to a nephrologist.
Baseline characteristics and the preferred mode of dia-
lysis remained concordant with the original trial [12],
consisting of a mean age of 63 ± 1 yrs and predominantly
Caucasian ethnicity (97.9%: one Asian and one Chinese
patient). Mortality was evaluated at a median of 126
months (mean of 146 ± 4.2 months) from presentation
to the renal service.
Thirty percent (29/94) of patients had been trans-
planted during the follow-up period and were therefore
censored in the survival cumulative analysis. At the time
of last follow-up 18 of the transplant patients were still
alive with a functioning renal allograft (62%); 2 hadTable 1 Mortality of study population over 10 yearsa
Total deaths over the 10 year study period including deaths in transpla




Dialysis related 3 (5%)
Treatment withdrawn 7 (13%)
Other 8 (14%)
a Deaths have been censored for live and deceased donor renal transplantation.experienced transplant failure and returned to haemodi-
alysis and 9 of those who received transplants died (31%;
6 cardiac deaths, 1 septicaemia, 1 calciphylaxis and 1 re-
lated to treatment withdrawal). For transplant patients,
the median time from first presentation to death was
8.9 years [mean of 9.8 ± 5.1 years], with an average wait
of 1.3 ± 0.4 years between first dialysis and transplant.
Survival from transplantation using Kaplan-Meier
showed a mean of 75 months (95% CI 57-92) and com-
pared with non-transplantation 63 months (95% CI
51-75), however this was not statistically significant
(p = 0.26) but subject to both bias in patient selection
and small numbers. These patients were then censored
from the data when examining mortality on further sur-
vival analysis.
The mortality rate at the end of the 10-year study
period was 60% (56/94). Causes of death are described
in Table 1 with cardiac related and infection accounting
for the majority (57%). There was an increase in the per-
centage of deaths from treatment withdrawal (13%) and
deaths from other causes (14%). The other categories in-
cluded malignancy and deaths related to chronic renal
failure whilst on dialysis.
Table 2 shows the comparison between survivors and
non-survivors at 10 years of dialysis. Survivors had a lower
mean age (53 years) compared to non-survivors (69 years).
Chi-squared analysis of the ordinate variables compared
vascular disease, diabetes, co-morbidity and haemoglobin
stratified into categories <110 g/L and >110 g/L. At 10
years, those with vascular disease, diabetes and >3 co-
morbidities were more likely to have a greater percentage
of non-survivors. There was no difference in percentage
survival between groups based on haemoglobin over 10
years. ANOVA analysis of continuous variables showed a
difference between serum creatinine (μmol/L), albumin
(g/L) and haemoglobin concentration (g/L) all at the start
of RRT. Non-survivors at 10 years had a lower serum cre-
atinine, lower albumin and haemoglobin at the start of
RRT. There was no significant difference between triglyc-
erides, calcium phosphate product, cholesterol, eGFR or
serum creatinine at referral to a nephrologist or eGFR at
commencement of RRT. Multivariate analysis using a Coxnt patients: 65 (69%)







Table 2 Univariate comparison of Factors between patients alive and dead at 10 years
Factor Alive at 10 years Dead at 10 years P-value Statistic
Age (years) a 53.2 (15.3) 69.0 (12.4) <0.001 t(92) = 5.494
Vascular disease – no (%)b 25 (52%) 23 (48%)
Vascular disease – yes (%)b 13 (28%) 33 (72%) 0.019 X2(1) = 5.535
Diabetes – no (%)b 29 (48%) 31 (52%)
Diabetes – yes (%)b 9 (27%) 25 (73%) 0.038 X2(1) = 4.307
Co-morbidity (>3) –no (%)b 31 (60%) 21 (40%)
Co-morbidity (>3) – yes (%)b 6 (15%) 35 (85%) <0.001 X2(1) = 20..085
Haemoglobin >110 g/l (%)b 5 (50%) 5 (50%) 0.514 X2(1) = 0.426
Haemoglobin <110 g/l (%)b 33 (39%) 51 (61%)
Creatinine at referral (μmol/l) a 483.8 (± 77.9) 411.1 (± 28.6) 0.321 t(92) = 0.999
eGFR at referral (ml/min/1.73 m2) a 18.6 (± 2.8) 19.3 (± 1.8) 0.838 t(92) = 0.205
Creatinine at start of RRT (μmol/l) a 903.6 (± 59.9) 757.8 (± 27.3) 0.016 t(92) = 2.455
eGFR at start of RRT (ml/min/1.73 m2) 6.35 (± 0.4) 6.35 (± 0.2) 0.988 t(92) = 0.015
Albumin at start of RRT (g/L) a 32.0 (± 4.9) 28.6 (± 5.7) 0.004 t(92) = 2.946
Haemoglobin at start of RRT (g/l) a 95.6 (± 2.8) 87.8 (± 2.2) 0.026 t(92) = 2.264
Cholesterol at start of RRT (mmol/l) a 5.2 (± 0.21) 5.0 (± 0.2) 0.685 t(92) = 0.406
Triglycerides at start of RRT (μmol/l) a 2.12 (± 0.22) 2.19 (± 0.16) 0.821 t(92) = 0.227
Calcium phosphate product at start of RRT (mmol2/l2) a 4.84 (± 0.29) 4.44 (± 0.22) 0.262 t(92) = 1.129
a Age: analysis using T-test.
b Chi-squared test.
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significance in this cohort, with the exception of age and
diabetes (Table 4), the assumption of proportional hazards
was verified by the log-log plots (Additional file 1).
On 10-year analysis, vascular disease and diabetes
remained independent risk factors and were predicative
of mortality (Table 3 and Additional file 1). From Kaplan-
Meier survival curves, patients with vascular disease had
a cumulative survival of 20% compared to 37% of those




95% CI P-value (Log rank
test –Mantel Cox)
Age <65 years 85.4 (69.2-
101.7)
Age >65 years 51.7 (40.1-63.3) 0.001
Vascular disease 52.3 (38.6-66.0)
No vascular disease 77.4 (63.891.0) 0.014








Diabetes mellitus 49.6 (33.6-66.6)
No diabetes m ellitus 74.0 (61.9-86.0) 0.032with diabetes had a cumulative survival of 22% compared
to 31% without diabetes (Figure 1B; p = 0.03). Those aged
greater than 65 years had a mean survival time of 51
months compared to those less than 65 years who had a
mean survival of 85 months (p = 0.001). No significant
difference was seen between those with the upper quar-
tile of calcium phosphate product and the lowest 3 quar-
tiles (Figure 1C; p = 0.7).
Additionally, patients stratified into high (>3) and low
(<3) co-morbidities, unplanned or referred presentations
and age groups stratified into greater and less than 65
years had marked differences in overall survival. Kaplan-
Meier survival curves showed that those with high
co-morbidities (>3) had a cumulative survival of 46%
compared to 9% (p < 0.0001). Comparing clinical presen-
tations, those with planned presentations had a cumula-
tive survival of 43% compared to 12% of those with
unplanned presentations (p = 0.004). Finally, those who
were older (>65) had worse survival rates after 10 years
of 15% compared to those in the younger age group,
which showed just over half of these patients were still
alive (52%) at 10 years (p = 0.001). Notably those who
were aged over 65 represented 73% of the high co-
morbidity cohort (30/41). Survival analysis of factors
including LVH, duration of follow up, smoking status
and type of dialysis and individual co-morbidities such
as cancer were non-significant at 10 years (data not
shown).
Table 4 Multivariate Analysis: Cox Proportional Hazards Model including age, co-morbidity group, presence or absence
of: diabetes, ischaemic heart disease, peripheral vascular disease, vascular disease, cancer or Chronic obstructive
pulmonary disease
B SE P value Hazard ratio 95% CI for Hazard ratio
Lower Upper
Age group (65 years) -.780 .352 .027 .458 .230 .914
High versus low comorbidity -.479 .373 .199 .619 .298 1.287
Diabetes -.814 .363 .025 .443 .218 .902
Ischaemic heart disease .235 .430 .585 1.265 .544 2.938
Cerebrovascular accident -.421 .423 .319 .656 .287 1.502
Peripheral vascular disease .399 .437 .361 1.491 .633 3.512
Vascular disease -.568 .514 .269 .567 .207 1.553
Cancer -.444 .404 .273 .642 .290 1.418
Chronic obstructive pulmonary disease -.424 .651 .514 .654 .183 2.342
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dictive of stating dialysis. Patients stratified to low risk
had a significantly longer time to dialysis; an average of
31 months (95% CI: 19.5-43.5) compared to high risk in-
dividuals who had an average time of 1 year (95% CI:
0.46-1.56). However patient mortality was not dependent
on risk calculator categorisation.
Kaplan-Meier survival analysis (Figure 2) showed that
the severe slope eGFR group was associated with an in-
creased mortality. The most severe slope deterioration
in eGFR was generated at 52.8 months (95% CI: 38.5-
67.1months) compared to 73.2 months (95% CI: 60.2-
86.3-months) for the lower quartiles: p = 0.05) but this
appeared to regress to the mean after 10 years.
Discussion
In this single centre study of a relatively elderly Cauca-
sian population receiving RTT, we have demonstrated
that diabetes and vascular disease remain strong predic-
tors of mortality, however contrary to the 5 year data a
high calcium-phosphate product no longer correlates
with mortality at 10 years. Vascular disease and sepsis
account for the majority of causes of death at all stages
of dialysis, accounting for 72% of the mortality seen at 5
years reducing to 57% at 10 years with a quarter of all
mortality (14/56) represented by cardiac disease.
At 10 years, treatment withdrawal and other causes of
death (including respiratory failure, pulmonary oedema
and sudden death) collectively have shown the greatest
proportional increase over the last 5 years (Table 1).
Treatment withdrawal has become a more significant
feature and is a common sequelae for those with end
stage renal failure (ESRF) on long-term RRT. In some
cohorts, treatment withdrawal has been described as an
increasingly common cause of death and is related to an
aging population with increased co-morbidities, such as
diabetes, or occurs in young individuals with severedisease [16,17]. Indeed the poor projected survival, re-
duced added benefit of therapy and increased cognitive
impairment seen in ESRF coupled with changing views
of clinicians has increased dialysis withdrawal rates. Al-
though we have investigated all-cause mortality as our
primary outcome, it is important to note that other end-
points for palliative care such as quality of life, ability to
make advanced directives and symptom management
are more clinically relevant.
The 5 year cumulative survival of patients with diabetes
and non-diabetics was 47% vs. 67% (p = 0.03) and then at
10 years was of 22% vs. 31% respectively (Figure 1B;
p = 0.03). At 5 years the paths of the two groups were diver-
gent, however the 10 year graph is following a divergent-
convergent path showing that therapy may be delaying the
natural progression of the underlying disease or that those
with diabetes may be experiencing early mortality.
The prevalence of diabetes mellitus in chronic kidney
disease (CKD) continues to increase and remains a
strong independent cardiovascular risk factor for patients
in the general population as well as on dialysis [18].
Hyperglycaemia, in combination to traditional risk fac-
tors not only potentates endothelial damage and inflam-
mation but in addition to diabetic mediators such as
reactive oxygen species and cytokines, affects gene struc-
ture and function, generating targets for novel epigenetic
therapeutics [19]. In addition to the recognised athero-
sclerotic processes responsible for these cardiac events, a
decreased cardiac velocity reserve has also been observed
in diabetic patients with CKD [20]. The importance of
atherosclerosis in this cohort has been well documented
and the presence of microalbuminuria has been recog-
nised as a surrogate marker of endothelial injury and
hence vascular damage seen in diabetic patients [21].
Intensive intervention of diabetes within a multidiscip-
linary team, in comparison to a conventional therapeutic
approach, has been shown not only to reduce mortality
Figure 1 Kaplain-Meier survival curves over 10 years for main
risk factors. (A) Vascular disease versus no vascular disease;
(B) Diabetes versus no diabetes; (C) Calcium phosphate
product quartiles.
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and macro-vascular complications of diabetes such as
neuropathy, nephropathy and retinopathy [22,23].
Debate remains about the optimal level of glycaemic
control for patients with diabetes on RRT [24]. Poor gly-
caemic control has been associated with increased cardio-
vascular deaths seen after transplantation [25]. In our
study 67% of those transplanted suffered cardiac deaths
(30% of whom were diabetic). Aggressive glycaemic control
has been shown to be detrimental generating a U-shaped
curve for HbA1c. When a patient’s HbA1c is persistently
lowered below 6% this is associated with adverse outcomes,
demonstrated not only in the general population, but in
those receiving dialysis as publicised in the Action to Con-
trol Cardiovascular Risk in type 2 Diabetes Mellitus trial
[26,27]. Although initially aimed at reducing microvascular
complications, the increasing cardiovascular mortality that
was seen meant the ACCORD trial had to be terminated
prematurely. Although near-normal glycaemia has not
been shown to reduce cardiovascular events in the short-
term [28], indeed the majority of our cardiovascular disease
mortality was seen within the first 5 years; follow up of
long-term randomised control studies is needed to deter-
mine optimal glycaemic control. Indeed HbA1c at low
levels do not necessarily only reflect diabetic treatment but
can also be a reflection of malnourishment. Changes in
body composition (e.g. muscle loss) may be associated with
outcomes but was not examined.
Our data is in agreement to the data presented in pre-
vious studies demonstrating that patients receiving RRT
with atherosclerotic vascular disease have higher mortal-
ity rates [29,30]. Also the number of risk factors for car-
diovascular disease increases with the stage of CKD [31].
Given that the pre-dialysis diagnosis of cardiovascular
disease predicted both early and late mortality, we specu-
late that the reemphasis of both prompt recognition and
management of cardiovascular risk factors during the
early stages of CKD maybe key to improving survival.
The importance of tight blood pressure regulation has
been shown to significantly reduce mortality and mor-
bidity [32]. However studies have raised concerns about
over aggressive blood pressure reduction as blood pres-
sure in relation to mortality, in a situation analogous to
diabetes, also follows a U-shaped curve [33,34]. Statins
have been used successfully in the general population to
reduce cardiovascular events by around 34%. In CKD
and dialysis patients the data is more complex. Initial
studies have shown reduced LDL levels in dialysis pa-
tients with no cardiovascular benefit [35], while the
Time to deaths (months)
Lower quartile slope eGFR
Severe slope eGFR
Figure 2 Kaplan-Meier Survival curves for predicting the mortality of those with severe slope eGFR deterioration (highest
quartile – lower line) prior to commencement of dialysis compared to the lower 3 quartiles of rate of eGFR progression (upper line).
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cardiovascular events in the overall cohort [36]. Sub-
group analysis however suggests once again no benefit in
dialysis patients [37]. Our analysis did not include blood
pressure but instead used cardiac end organ markers of
hypertension to indicate the presence of cardiac hyper-
trophy (ECG changes or cardiac echo). Direct relationship
between levels of ambulatory blood pressure and cardio-
vascular events has not been clearly established by con-
trolled studies in dialysis patients and there is a lack of a
significant correlation between blood pressure and car-
diovascular events in dialysis patients and no predictive
value for mortality. It is also well recognised that blood
pressure is subject to error in measurement and con-
sistency and lack of standardization of various factors: the
auscultatory method of blood pressure measurement eg
Korotkoff sounds; patient position during blood pressure
assessment; appropriate cuff size to ensure the cuff blad-
der encircles at least 80% of the arm is not always per-
formed [38,39].
Traditional risk factors have been the mainstay of car-
diovascular disease primary prevention identified in the
Framingham Heart Study. However there is debate
whether the same relative risks apply to a dialysis popula-
tion in the secondary prevention of cardiovascular dis-
ease. The presence of “renal-specific” non-traditional risk
factors including endothelial dysfunction, inflammation,
oxidative stress, insulin resistance, anaemia and changes
in vitamin D metabolism may play an even more import-
ant role in cardiovascular disease progression in CKD
[40]. Therefore in considering the overall cardiovascular
risk factors, a risk score specific to this population whilstincorporating a wide range of factors, including those
prior to dialysis (such as renal function at the start of dia-
lysis and microalbuminuria), may aid the stratification of
high risk patients [41,42].
Application of the Tangri risk calculator was predictive
of commencing RRT but not mortality while slope change
in eGFR was more predictive of mortality suggesting
rapid progressors to RRT are more likely to die. This
would be in keeping with CKD stage in relation to cardio-
vascular risk [43] and potentially a future non-traditional
risk factor to modify cardiovascular risk.
Although, in the previous analysis an elevated calcium
phosphate product had a significant effect on early mor-
tality and at 5years, validating previous findings in pa-
tients with ESRF [44], this was no longer the case after
10 years of follow up (Figure 1C; p = 0.7), reflecting other
studies with a similar case mix and follow up [45]. One
hypothesis is perhaps that calcium phosphate is an inde-
pendent risk factor, or proxy, for those already with sig-
nificant vascular disease. Those with higher proportions
of vascular disease coupled with calcium and phosphate’s
reflecting potential statistical predictors of cardiac calcifi-
cation and mortality may have already perished at 1 and
5 years [46]. Indeed more aggressive management of vas-
cular risk factors may account for the reduced mortality
seen at 10 years. This is, however, speculation of an inde-
pendent risk factor recorded on first dialysis and would
require serial calcium phosphate measurements within a
randomised control trial to validate this hypothesis.
There is emerging interest between vitamin D, FGF-23
and Klotho and their relation to cardiovascular risk in pa-
tients receiving RRT. An understanding how these factors
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be influential in modifying patients’ overall vascular risk
[47,48]. A reduction in Klotho and elevation in FGF-23
culminate in reduced vitamin D levels and increased
phosphate with subsequent increased risk of vascular
calcification [49]. From our study perspective, levels of
these signalling messengers may have changed with RRT
or been influenced by the inherent genetic variations seen
in different patient sub-groups altering expression of
these factors and conferring protection - a concept pro-
posed by those undertaking molecular biological assays
with Klotho [50,51].
Conclusions
Diabetes and vascular disease remain challenging risk fac-
tors in RRT patients. Vascular calcification in relation to a
higher calcium-phosphate product is a potential and im-
portant modifiable risk factor to prevent early mortality
on RRT for those patients already at significant cardiovas-
cular risk. One might speculate that early aggressive
intervention will be necessary to influence mortality in
subsequent cohorts.
The burden of vascular disease remains of key import-
ance for patients. Modifying the risk profile and inten-
sive intervention accounts for the reduced numbers of
cardiovascular events seen in the last 5 years of this
study. It however seems more likely that the distribution
of causes of death changes because those who die of car-
diovascular or infectious causes die earlier. Determining
modifiable risk factors and optimal management for
those who are more likely to suffer from early demise
will be central to changing the overall mortality.
Limitations to the study
This study has several limitations. One acknowledges
that this was an observational cohort study in a rela-
tively elderly Caucasian group of patients and that small
numbers were used. In particular a significant limitation
was the use of risk factors taken from baseline only as it
should be acknowledged that these factors may change
over time and the associations may weaken with time.
However it does highlight some interesting findings.
Therefore prospective studies are necessary to investi-
gate any potential causal relationships between both
traditional and non-traditional risk factors that we have
described with cardiovascular end-points. Larger num-
bers would be necessary to remove possible type 2
errors occurring and to see if interventions to reduce
risk factors lead to overt reductions in cardiovascular
risk. Other limitations include confounding by both
known and unknown factors; misclassification of the
outcome (cause of death only). Finally a weakness is the
lack of longitudinal data on all the risk factors, bio-
markers (such as Ca-P), vascular access, and comorbidconditions which may be less relevant closer to death or
change during RRT.
Short summary
Vascular and diabetic risk factors are strongly predictive of
mortality in dialysis patients at 10 years, whereas calcium
and phosphate are no longer. Treatment withdrawal has
become a more salient feature. As patient’s risk profile
changes over time, identifying modifiable risk factors at
different stages of disease progression will help reduce
morbidity and mortality of those on dialysis.
Additional file
Additional file 1: Table 3 analysis. Assumption of Proportional
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